Genetics of the human gut microbiome might be the next big thing

e coli
Colorized low-temperature electron micrograph of a cluster of E. coli bacteria.

Corey Goodman sees financial opportunity in strange places, specifically the human bowel. In 2010 the former president of Pfizer’s innovation center founded Second Genome, a company dedicated to identifying the varieties of bacteria in stool samples and manipulating them to improve human health. Goodman’s start-up has raised millions of dollars from venture capitalists. Earlier this year, Johnson and Johnson partnered with Second Genome, becoming the first big pharma company to invest heavily in the microbiome.

There are good reasons the smart money may be on researching human waste. Describing the microbiome could lead to treatments for conditions like celiac disease and the nebulous but widespread irritable bowel syndrome. Even more lucrative would be a new weight loss medication. The market for weight loss products is worth more than $60 billion.

Read the full, original story here: Big-Bucks Bacteria

Additional Resources:

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...
Untitled

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend